Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have been given a consensus rating of “Buy” by the eight analysts that are presently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $24.43.

Several brokerages have issued reports on TEVA. Barclays lowered their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, April 23rd. Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. Finally, UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $16.95 on Friday. The company’s fifty day moving average price is $15.35 and its 200 day moving average price is $17.41. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The firm has a market capitalization of $19.22 billion, a P/E ratio of -11.69, a P/E/G ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. During the same period last year, the business earned $0.48 EPS. Teva Pharmaceutical Industries’s revenue for the quarter was up 1.9% compared to the same quarter last year. As a group, sell-side analysts predict that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Oarsman Capital Inc. purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $29,000. Golden State Wealth Management LLC purchased a new stake in Teva Pharmaceutical Industries during the first quarter worth about $39,000. New Age Alpha Advisors LLC purchased a new stake in Teva Pharmaceutical Industries during the first quarter worth about $43,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter worth about $44,000. Finally, Compagnie Lombard Odier SCmA purchased a new stake in Teva Pharmaceutical Industries during the first quarter worth about $54,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.